Menu
 
Research menu
Jump to menu

Publications:  Dr Klaus Schmierer

Carassiti D, Altmann DR, Petrova N et al.(2018). Neuronal loss, demyelination and volume change in the multiple sclerosis neocortex. Neuropathol Appl Neurobiol vol. 44, (4) 377-390.
10.1111/nan.12405
http://qmro.qmul.ac.uk/xmlui/handle/123456789/23097
Yildiz O, Mao Z, Adams A et al.(2018). Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine. Mult Scler Relat Disord vol. 24, 20-27.
10.1016/j.msard.2018.05.010
Middleton RM, Rodgers WJ, Chataway J et al.(2018). Validating the portal population of the United Kingdom Multiple Sclerosis Register. Mult Scler Relat Disord vol. 24, 3-10.
10.1016/j.msard.2018.05.015
Stavrou M, Francis L, Tshuma N et al.(2018). Neuromyelitis optica spectrum disorder presenting as rhomboencephalitis. BMJ Case Rep vol. 2018,
10.1136/bcr-2017-222255
Jacobs BM, Giovannoni G, Schmierer K(2018). No Evident Disease Activity-More Than a Risky Ambition?. JAMA Neurol
10.1001/jamaneurol.2018.0829
Petrova N, Carassiti D, Altmann DR et al.(2018). Axonal loss in the multiple sclerosis spinal cord revisited. Brain Pathol vol. 28, (3) 334-348.
10.1111/bpa.12516
http://qmro.qmul.ac.uk/xmlui/handle/123456789/22903
Ceronie B, Jacobs BM, Baker D et al.(2018). Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells. J Neurol vol. 265, (5) 1199-1209.
10.1007/s00415-018-8830-y
http://qmro.qmul.ac.uk/xmlui/handle/123456789/36729
Keddie S, Adams A, Kelso ARC et al.(2018). No laughing matter: subacute degeneration of the spinal cord due to nitrous oxide inhalation. J Neurol vol. 265, (5) 1089-1095.
10.1007/s00415-018-8801-3
http://qmro.qmul.ac.uk/xmlui/handle/123456789/35883
Cerqueira JJ, Compston DAS, Geraldes R et al.(2018). Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?. J Neurol Neurosurg Psychiatry
10.1136/jnnp-2017-317509
http://qmro.qmul.ac.uk/xmlui/handle/123456789/36484
Birkl C, Carassiti D, Hussain F et al.(2018). Assessment of ferritin content in multiple sclerosis brains using temperature-induced R*2 changes. Magn Reson Med vol. 79, (3) 1609-1615.
10.1002/mrm.26780
http://qmro.qmul.ac.uk/xmlui/handle/123456789/25143
Schmierer K, McDowell A, Petrova N et al.(2018). Quantifying multiple sclerosis pathology in post mortem spinal cord using MRI. Neuroimage
10.1016/j.neuroimage.2018.01.052
Webb EJD, Meads D, Eskyte I et al.(2018). A Systematic Review of Discrete-Choice Experiments and Conjoint Analysis Studies in People with Multiple Sclerosis. Patient
10.1007/s40271-017-0296-y
http://qmro.qmul.ac.uk/xmlui/handle/123456789/31487
Dubuisson N, Baker D, Kang AS et al.(2017). Alemtuzumab depletion failure can occur in multiple sclerosis. Immunology
10.1111/imm.12879
http://qmro.qmul.ac.uk/xmlui/handle/123456789/31849
Dubuisson N, Baker D, Thomson A et al.(2017). Disease modification in advanced MS: Focus on upper limb function. Mult Scler vol. 23, (14) 1956-1957.
10.1177/1352458517717811
http://qmro.qmul.ac.uk/xmlui/handle/123456789/25093
Baker D, Giovannoni G, Schmierer K(2017). Marked neutropenia: significant but rare in people with multiple sclerosis after alemtuzumab treatment. Multiple Sclerosis and Related Disorders
10.1016/j.msard.2017.09.028
Campion T, Smith RJP, Altmann DR et al.(2017). FLAIR* to visualize veins in white matter lesions: A new tool for the diagnosis of multiple sclerosis?. Eur Radiol vol. 27, (10) 4257-4263.
10.1007/s00330-017-4822-z
http://qmro.qmul.ac.uk/xmlui/handle/123456789/22582
Dubuisson N, Bauer A, Buckley M et al.(2017). Validation of an environmentally-friendly and affordable cardboard 9-hole peg test. Mult Scler Relat Disord vol. 17, 172-176.
10.1016/j.msard.2017.08.002
http://qmro.qmul.ac.uk/xmlui/handle/123456789/29763
Baker D, Herrod SS, Alvarez-Gonzalez C et al.(2017). Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab. JAMA Neurol vol. 74, (8) 961-969.
10.1001/jamaneurol.2017.0676
http://qmro.qmul.ac.uk/xmlui/handle/123456789/25508
Afolabi D, Albor C, Zalewski L et al.(2017). Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis. Mult Scler1352458517726380-1352458517726380.
10.1177/1352458517726380
http://qmro.qmul.ac.uk/xmlui/handle/123456789/25832
Baker D, Herrod SS, Alvarez-Gonzalez C et al.(2017). Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol Neuroimmunol Neuroinflamm vol. 4, (4)
10.1212/NXI.0000000000000360
http://qmro.qmul.ac.uk/xmlui/handle/123456789/24514
Pakpoor J, Goldacre R, Schmierer K et al.(2017). Psychiatric disorders in children with demyelinating diseases of the central nervous system. Mult Scler
10.1177/1352458517719150
http://qmro.qmul.ac.uk/xmlui/handle/123456789/25649
BAKER D, Herrod SS, Alvarez-Gonzalez C et al.(2017). Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab. JAMA Neurology vol. 74, (8)
10.1001/jamaneurol.2017.0676
http://qmro.qmul.ac.uk/xmlui/handle/123456789/25508
BAKER D, SCHMIERER K, Herrod S et al.(2017). Both cladribine and alemtuzumab may effect multiple sclerosis via B cell depletion. Neurology: Neuroimmunology and Neuroinflammation vol. 4, (4)
10.​1212/​NXI.​0000000000000360
http://qmro.qmul.ac.uk/xmlui/handle/123456789/23704
Alvarez-Gonzalez C, Adams A, Mathews J et al.(2017). Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis. Annals of Clinical and Translational Neurology
10.1002/acn3.410
http://qmro.qmul.ac.uk/xmlui/handle/123456789/23283
Giovannoni G, Cutter G, Pia-Sormani M et al.(2017). Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. Multiple Sclerosis and Related Disorders vol. 12, 70-78.
10.1016/j.msard.2017.01.007
http://qmro.qmul.ac.uk/xmlui/handle/123456789/23518
Baker D, Marta M, Pryce G et al.(2017). Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. EBioMedicine vol. 16, 41-50.
10.1016/j.ebiom.2017.01.042
http://qmro.qmul.ac.uk/xmlui/handle/123456789/23134
Albor C, du Sautoy T, Kali Vanan N et al.(2017). Ethnicity and prevalence of multiple sclerosis in east London. Mult Scler vol. 23, (1) 36-42.
10.1177/1352458516638746
http://qmro.qmul.ac.uk/xmlui/handle/123456789/13579
Stavrou M, Smith D, Shaw P et al. (2016). REAL WORLD EXPERIENCE OF FINGOLIMOD IN MULTIPLE SCLEROSIS: THE LONDON AUDIT. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 87,
10.1136/jnnp-2016-315106.160
http://qmro.qmul.ac.uk/xmlui/handle/123456789/25727
Davis A, Turner B, Ramadhan M et al. (2016). THE BURDEN OF BLADDER DYSFUNCTION IN MULTIPLE SCLEROSIS: A MULTI-CENTRE AUDIT. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 87,
10.1136/jnnp-2016-315106.127
Alvarez-Gonzalez C, Allen-Philbey K, Mathews J et al. (2016). TREATING MULTIPLE SCLEROSIS WITH CLADRIBINE. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 87,
10.1136/jnnp-2016-315106.121
Dobson R, Ramagopalan S, Topping J et al.(2016). A Risk Score for Predicting Multiple Sclerosis. PLoS One vol. 11, (11) Article 0164992, e0164992-e0164992.
10.1371/journal.pone.0164992
http://qmro.qmul.ac.uk/xmlui/handle/123456789/18832
Pakpoor J, Wotton CJ, Schmierer K et al.(2016). Gender identity disorders and multiple sclerosis risk: A national record-linkage study. MULTIPLE SCLEROSIS JOURNAL vol. 22, (13) 1759-1762.
10.1177/1352458515627205
http://qmro.qmul.ac.uk/xmlui/handle/123456789/23427
Pakpoor J, Wotton CJ, Schmierer K et al. (2016). Gender identity disorders and multiple sclerosis risk: A national record-linkage study. Mult Scler. vol. 22, 1759-1762.
10.1177/1352458515627205
http://qmro.qmul.ac.uk/xmlui/handle/123456789/11114
Thomson A, Giovannoni G, Marta M et al. (2016). Importance of upper limb function in advanced multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL. vol. 22, 676-676.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/25226
Rejdak K, Mitosek-Szewczyk K, Prus K et al. (2016). Induction therapy of relapsing secondary multiple sclerosis using generic cladribine. MULTIPLE SCLEROSIS JOURNAL. vol. 22, 593-594.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/25224
Gold J, Marta MC, Meier UC et al. (2016). Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results. MULTIPLE SCLEROSIS JOURNAL. vol. 22, 188-189.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/25994
Marta M, MacManus D, Yousry T et al. (2016). Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study results. MULTIPLE SCLEROSIS JOURNAL. vol. 22, 188-188.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/25993
Pakpoor J, Goldacre R, Schmierer K et al. (2016). Risks of psychiatric disorders in children and young adults with demyelinating diseases of the central nervous system: a national record-linkage study. MULTIPLE SCLEROSIS JOURNAL. vol. 22, 17-17.
Petrova N, Carassiti D, Scaravilli F et al. (2016). Synaptic loss in the MS spinal cord: a key driver of disease progression?. MULTIPLE SCLEROSIS JOURNAL. Conference: ECTRIMS 2016 Committees (UCL Institute of Neurology, London, UK) from: 14/09/2016 to: 17/09/2016, vol. 22, 80-80.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/25227
Alvarez-Gonzalez C, Allen-Philbey K, Mathews J et al. (2016). Treating multiple sclerosis with generic cladribine. MULTIPLE SCLEROSIS JOURNAL. vol. 22, 604-605.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/25052
Campion T, Schmierer K(2016). Re: The effect of venous anatomy on the morphology of multiple sclerosis lesions: a susceptibility-weighted imaging study. Clinical Radiology
10.1016/j.crad.2016.05.021
http://qmro.qmul.ac.uk/xmlui/handle/123456789/13800
Giovannoni G, Marta M, Davis A et al.(2016). Switching patients at high risk of PML from natalizumab to another disease-modifying therapy. Practical Neurologypractneurol-2015-001-practneurol-2015-001.
10.1136/practneurol-2015-001355
http://qmro.qmul.ac.uk/xmlui/handle/123456789/14950
Pakpoor J, Wotton C, Schmierer K et al. (2016). Gender Identity Disorders and Multiple Sclerosis Risk: A National Record Linkage Study. NEUROLOGY. vol. 86,
Pakpoor J, Wotton C, Schmierer K et al. (2016). Gender Identity Disorders and Multiple Sclerosis Risk: A National Record-Linkage Study. NEUROLOGY. vol. 86,
Pakpoor J, Wotton C, Schmierer K et al. (2016). Gender identity Disorders and Multiple Sclerosis Risk: A National Record-Linkage Study. NEUROLOGY. vol. 86,
Raftopoulos R, Hickman S, Toosy A et al. (2016). Prognostic Factors Associated with Axonal Loss after Optic Neuritis. NEUROLOGY. vol. 86,
SCHMIERER K, Albor C, du Sautoy T et al.(2016). Ethnicity and prevalence of multiple sclerosis in east London. Multiple Sclerosis Journal
10.1177/1352458516638746
http://qmro.qmul.ac.uk/xmlui/handle/123456789/14965
Raftopoulos R, Hickman SJ, Toosy A et al.(2016). Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol vol. 15, (3) 259-269.
10.1016/S1474-4422(16)00004-1
http://qmro.qmul.ac.uk/xmlui/handle/123456789/11119
Davis A, Dobson R, Kaninia S et al.(2016). Atraumatic needles for lumbar puncture: why haven't neurologists changed?. Pract Neurol vol. 16, (1) 18-22.
10.1136/practneurol-2014-001055
http://qmro.qmul.ac.uk/xmlui/handle/123456789/10032
Pakpoor J, Disanto G, Altmann DR et al.(2015). No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm vol. 2, (6)
10.1212/NXI.0000000000000158
http://qmro.qmul.ac.uk/xmlui/handle/123456789/12681
Thomson A, Davis A, Paterson A et al. (2015). DESIGNING AN INFORMATION RESOURCE TO EXPLAIN DIAGNOSTIC LUMBAR PUNCTURE AND PROMOTE BEST PRACTICE. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 86,
10.1136/jnnp-2015-312379.3
http://qmro.qmul.ac.uk/xmlui/handle/123456789/11116
Albor C, du Sautoy T, Vanan NK et al. (2015). ETHNICITY AND MULTIPLE SCLEROSIS PREVALENCE IN EAST LONDON. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 86,
10.1136/jnnp-2015-312379.100
http://qmro.qmul.ac.uk/xmlui/handle/123456789/11117
Carassiti D, Pakkenberg B, Scaravilli F et al. (2015). Cortical atrophy predicts neuronal loss in MS: a post mortem study using unbiased sampling. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 423-424.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/11115
Giovannoni G, Brex P, Sumra M et al. (2015). Glatiramer acetate slows disability progression - results from a 6-year analysis of the UK Risk Sharing Scheme. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 800-801.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/11118
Raftopoulos R, Rangarajan A, Chen C-L et al. (2015). Sodium channel blockade with phenytoin has a neuroprotective effect on the ganglion cell complex after acute optic neuritis. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 273-274.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/12094
Scolding N, Barnes D, Cader S et al.(2015). Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol vol. 15, (4) 273-279.
10.1136/practneurol-2015-001139
http://qmro.qmul.ac.uk/xmlui/handle/123456789/11980
Giovannoni G, Turner B, Gnanapavan S et al.(2015). Is it time to target no evident disease activity (NEDA) in multiple sclerosis?. Mult Scler Relat Disord vol. 4, (4) 329-333.
10.1016/j.msard.2015.04.006
http://qmro.qmul.ac.uk/xmlui/handle/123456789/8421
Thomson A, Davis A, Paterson A et al. (2015). Designing an information resource to explain diagnostic lumbar puncture and promote best practice. EUROPEAN JOURNAL OF NEUROLOGY. vol. 22, 491-492.
Raftopoulos R, Hickman S, Toosy A et al. (2015). Neuroprotection with phenytoin in acute optic neuritis: results of a phase II randomised controlled trial. EUROPEAN JOURNAL OF NEUROLOGY. vol. 22, 48-48.
Raciborska D, Turner B, Schmierer K (2015). Switching MS patients from natalizumab to fingolimod therapy: comparison of short and prolonged washout periods. EUROPEAN JOURNAL OF NEUROLOGY. vol. 22, 350-350.
Schmierer K (2015). New Perspectives on Inflammatory CNS Disease Therapies. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 802-803.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/7799
Schmierer K(2015). Pathological and MRI markers of deterioration. MULTIPLE SCLEROSIS JOURNAL vol. 21, (6) 799-800.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/9630
Giovannoni G, Baker D, Schmierer K(2015). The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis?. Mult Scler Relat Disord vol. 4, (1) 3-5.
10.1016/j.msard.2014.11.005
http://qmro.qmul.ac.uk/xmlui/handle/123456789/11979
Pakpoor J, Goldacre R, Schmierer K et al.(2014). Testicular hypofunction and multiple sclerosis: Cause or consequence? Reply. Ann Neurol vol. 76, (5) 765-766.
10.1002/ana.24275
http://qmro.qmul.ac.uk/xmlui/handle/123456789/7243
Pakpoor J, Disanto G, Altmann DR et al. (2014). CANCER RISK IN MULTIPLE SCLEROSIS PATIENTS TAKING CLADRIBINE. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 85,
10.1136/jnnp-2014-309236.140
http://qmro.qmul.ac.uk/xmlui/handle/123456789/7246
Schmierer K, Marta M, Turner BP et al. (2014). THE USE OF MAGNETIC RESONANCE IMAGING (MRI) IN THE MANAGEMENT OF MULTIPLE SCLEROSIS IN THE UK. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 85,
10.1136/jnnp-2014-309236.131
http://qmro.qmul.ac.uk/xmlui/handle/123456789/7245
Pakpoor J, Goldacre R, Schmierer K et al.(2014). Testicular hypofunction and multiple sclerosis risk: a record-linkage study. Ann Neurol vol. 76, (4) 625-628.
10.1002/ana.24250
http://qmro.qmul.ac.uk/xmlui/handle/123456789/6339
Giovannoni G, Baker D, Schmierer K(2014). Simvastatin in patients with progressive multiple sclerosis. Lancet vol. 384, (9947)
10.1016/S0140-6736(14)61621-4
http://qmro.qmul.ac.uk/xmlui/handle/123456789/11982
Campion T, Smith P, Altmann DR et al. (2014). FLAIR* for the non-invasive histological diagnosis of MS. MULTIPLE SCLEROSIS JOURNAL. vol. 20, 289-290.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/12022
Schmierer K (2014). Repurposing drugs for disease modification in multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL. vol. 20, 35-36.
Carassiti D, Papachatzaki M, Scaravilli F et al. (2014). The loss of neurons over the whole MS neocortex. MULTIPLE SCLEROSIS JOURNAL. vol. 20, 59-59.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/9629
Carassiti D, Petrova N, Al-Zawawi S et al. (2014). The relationship between axonal loss and demyelination in the MS spinal cord. MULTIPLE SCLEROSIS JOURNAL. vol. 20, 366-366.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/8024
Gnanapavan S, Jaunmuktane Z, Baruteau KP et al.(2014). A rare presentation of atypical demyelination: tumefactive multiple sclerosis causing Gerstmann's syndrome. BMC Neurol vol. 14,
10.1186/1471-2377-14-68
http://qmro.qmul.ac.uk/xmlui/handle/123456789/7244
Wallner-Blazek M, Rovira A, Filippi M et al.(2014). Erratum to: Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis. J Neurol vol. 261, (4) 848-849.
10.1007/s00415-014-7279-x
Altmann DR, Button T, Schmierer K et al.(2014). Sample sizes for lesion magnetisation transfer ratio outcomes in remyelination trials for multiple sclerosis. Mult Scler Relat Disord vol. 3, (2) 237-243.
10.1016/j.msard.2013.09.007
http://qmro.qmul.ac.uk/xmlui/handle/123456789/11981
Davis A, Dobson R, Kaninia S et al.(2014). Change practice now! Using atraumatic needles to prevent post lumbar puncture headache. Eur J Neurol vol. 21, (2) 305-311.
10.1111/ene.12307
http://qmro.qmul.ac.uk/xmlui/handle/123456789/12000
Dobson R, Rudick RA, Turner B et al.(2014). Assessing treatment response to interferon-beta Is there a role for MRI?. NEUROLOGY vol. 82, (3) 248-254.
10.1212/WNL.0000000000000034
Dobson R, Rudick RA, Turner B et al.(2014). Assessing treatment response to interferon-β: is there a role for MRI?. Neurology vol. 82, (3) 248-254.
10.1212/WNL.0000000000000036
Papachatzaki MM, Ali N, Arshad Q et al.(2013). Progressive ataxia with oculo-palatal tremor and optic atrophy. J Neurol vol. 260, (11) 2903-2905.
10.1007/s00415-013-7136-3
http://qmro.qmul.ac.uk/xmlui/handle/123456789/9611
Albor C, Richards O, Ramagopalan S et al.(2013). Using routine point-of-care data for research: the East london multiple sclerosis cohort. J Neurol Neurosurg Psychiatry vol. 84, (11)
10.1136/jnnp-2013-306573.170
http://qmro.qmul.ac.uk/xmlui/handle/123456789/7384
Carassiti D, Papachatzaki M, Scaravilli F et al. (2013). Accurate estimates of whole brain neuronal loss in multiple sclerosis using unbiased quantitative histology. MULTIPLE SCLEROSIS JOURNAL. vol. 19, 161-161.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/7241
Raftopoulos RE, Hickman S, Toosy A et al. (2013). Optical coherence tomography (OCT), visual function and MRI measures in acute optic neuritis: baseline data from a clinical trial. MULTIPLE SCLEROSIS JOURNAL. vol. 19, 8-9.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/9614
Papachatzaki MM, Carassiti D, McDowell A et al. (2013). Stereological estimates of neuronal loss in the primary motor cortex of multiple sclerosis patients. MULTIPLE SCLEROSIS JOURNAL. vol. 19, 571-572.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/7240
Wallner-Blazek M, Rovira A, Fillipp M et al.(2013). Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis. J Neurol vol. 260, (8) 2016-2022.
10.1007/s00415-013-6918-y
http://qmro.qmul.ac.uk/xmlui/handle/123456789/7239
Schmierer K, Papachatzaki MM(2013). A single lesion-And yet MS?. Mult Scler Relat Disord vol. 2, (3) 154-155.
10.1016/j.msard.2013.02.002
http://qmro.qmul.ac.uk/xmlui/handle/123456789/11978
Yiannakas MC, Tozer DJ, Schmierer K et al.(2013). ADvanced IMage Algebra (ADIMA): a novel method for depicting multiple sclerosis lesion heterogeneity, as demonstrated by quantitative MRI. Mult Scler vol. 19, (6) 732-741.
10.1177/1352458512462074
http://qmro.qmul.ac.uk/xmlui/handle/123456789/10911
Valdueza JM, Doepp F, Schreiber SJ et al.(2013). What went wrong? The flawed concept of cerebrospinal venous insufficiency. J Cereb Blood Flow Metab vol. 33, (5) 657-668.
10.1038/jcbfm.2013.31
http://qmro.qmul.ac.uk/xmlui/handle/123456789/10910
Papachatzaki MM, Ali N, Peppas Y et al. (2012). A NEW PHENOTYPE OF PAPT: PROGRESSIVE ATAXIA, PALATAL TREMOR AND OPTIC ATROPHY. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 83,
10.1136/jnnp-2012-304200a.52
Mougin OE, Mistry N, Papachatzaki MM et al. (2012). MULTI-MODAL MRI AT 7T TO DETECT AND QUANTIFY MULTIPLE SCLEROSIS CORTICAL GREY MATTER PATHOLOGY. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 83,
10.1136/jnnp-2012-304200a.137
Davis A, Espasandin MD, Schmierer K (2012). OVER 100 YEARS OF POST LUMBAR PUNCTURE HEADACHE, AND COUNTING. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 83,
10.1136/jnnp-2012-304200a.24
Raftopoulos RE, Hickman S, Toosy A et al. (2012). A phase II double-blind, randomised, placebo-controlled trial of neuroprotection with phenytoin in acute optic neuritis. MULTIPLE SCLEROSIS JOURNAL. vol. 18, 442-443.
Davis A, Dobson R, Espasandin M et al. (2012). Cerebrospinal fluid biomarkers as outcome measures in clinical trials of MS: The significance of post lumbar puncture headaches. MULTIPLE SCLEROSIS JOURNAL. vol. 18, 237-238.
Altmann DR, Button T, Schmierer K et al. (2012). Sample sizes for lesion magnetisation transfer ratio outcome measures in remyelination trials for multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL. vol. 18, 470-470.
Dobson R, Meier UC, Schmierer K et al. (2012). DO SIBLINGS OF PEOPLE WITH MULTIPLE SCLEROSIS (MS) HAVE MARKERS OF MS RISK?. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 83,
10.1136/jnnp-2011-301993.173
http://qmro.qmul.ac.uk/xmlui/handle/123456789/7015
Kappos L, Gold R, Miller DH et al.(2012). Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study. Mult Scler vol. 18, (3) 314-321.
10.1177/1352458511421054
SCHMIERER K(2012). Magnetic resonance imaging in multiple sclerosis. Multiple Sclerosis (Visual Guide for Clinicians), Editors: Dobson, R, Giovannoni, G, Atlas Medical Publishing
Petzold A, Tozer DJ, Schmierer K(2011). Axonal damage in the making: neurofilament phosphorylation, proton mobility and magnetisation transfer in multiple sclerosis normal appearing white matter. Exp Neurol vol. 232, (2) 234-239.
10.1016/j.expneurol.2011.09.011
Dobson R, Meier UC, Schmierer K et al.(2011). Do siblings have markers of multiple sclerosis risk?. MULTIPLE SCLEROSIS JOURNAL vol. 17, S86-S86.
Schmierer K, Tozer D, Petzold A(2011). In multiple sclerosis' protein phosphorylation competes with the free proton binding capacity in post-mortem brain tissue. MULTIPLE SCLEROSIS JOURNAL vol. 17, S503-S503.
Schmierer K, Tozer DJ, Petzold A (2011). Axonal Damage in the Making: Neurofilament Phosphorylation and Magnetization Transfer in Multiple Sclerosis Non-Lesional White Matter. NEUROLOGY. vol. 76, A358-A358.
MacManus DG, Miller DH, Kappos L et al.(2011). BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. J Neurol vol. 258, (3) 449-456.
10.1007/s00415-010-5777-z
Connolly F, Paul F, Valdueza JM et al. (2011). Patients with Multiple Sclerosis Do Not Suffer from Cerebro-Cervical Venous Congestion. NEUROLOGY. vol. 76, A171-A171.
Ugradar SY, Parkes H, So PW et al. (2011). Quantifying Remyelination in Multiple Sclerosis Using High Field (9.4T) Magnetic Resonance Imaging. NEUROLOGY. vol. 76, A172-A172.
Schmierer K (2010). Imaging of human inflammatory neurodegenerative disorders. IMMUNOLOGY. vol. 131, 5-5.
Doepp F, Paul F, Valdueza JM et al.(2010). Reply. Ann Neurol vol. 68, (6)
10.1002/ana.22182
Schmierer K, Thavarajah JR, An SF et al.(2010). Effects of formalin fixation on magnetic resonance indices in multiple sclerosis cortical gray matter. J Magn Reson Imaging vol. 32, (5) 1054-1060.
10.1002/jmri.22381
Doepp F, Paul F, Valdueza JM et al.(2010). Multiple Sclerosis Appears To Be Associated with Cerebral Venous Abnormalities Reply. ANN NEUROL vol. 68, (4) 561-562.
10.1002/ana.22181
Doepp F, Paul F, Valdueza JM et al.(2010). No cerebrocervical venous congestion in patients with multiple sclerosis. Ann Neurol vol. 68, (2) 173-183.
10.1002/ana.22085
Schmierer K, Parkes HG, So P-W et al.(2010). High field (9.4 Tesla) magnetic resonance imaging of cortical grey matter lesions in multiple sclerosis. Brain vol. 133, (Pt 3) 858-867.
10.1093/brain/awp335
Schmierer K (2009). HIGH FIELD MRI REVEALS MULTIPLE SCLEROSIS CORTICAL GREY MATTER LESIONS AND ALLOWS QUANTITATIVE ASSESSMENT OF NEURONS AND AXONS. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 80,
10.1136/jnnp.2009.195180w
Parkes H, So PW, Brandner S et al. (2009). Quantifying cortical pathology in multiple sclerosis using high-field MRI. MULTIPLE SCLEROSIS. vol. 15, S91-S91.
Farrell RA, Antony D, Wall GR et al.(2009). Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. NEUROLOGY vol. 73, (1) 32-38.
10.1212/WNL.0b013e3181aa29fe
Fisniku LK, Altmann DR, Cercignani M et al.(2009). Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis. Mult Scler vol. 15, (6) 668-677.
10.1177/1352458509103715
Goodman AD, Rossman H, Bar-Or A et al.(2009). GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology vol. 72, (9) 806-812.
10.1212/01.wnl.0000343880.13764.69
Schmierer K, Parkes HG, So P-W(2009). Direct visualization of remyelination in multiple sclerosis using T2-weighted high-field MRI. Neurology vol. 72, (5)
10.1212/01.wnl.0000341878.80395.39
Schmierer K(2008). Commentary on: "Dirty-appearing white matter in multiple sclerosis. J NEUROL vol. 255, (11) 1812-1812.
10.1007/s00415-008-0001-0
Schmierer K(2008). Commentary on: "Dirty-appearing white matter in multiple sclerosis: preliminary observations of myelin phospholipid and axonal loss", by G. R. W. Moore, et al. in J Neurol (2008) 255: DOI 10.1007/s00415-008-0002-z. J Neurol vol. 255, (11)
Kappos L, Gold R, Miller DH et al.(2008). Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet vol. 372, (9648) 1463-1472.
10.1016/S0140-6736(08)61619-0
Petzold A, Gveric D, Groves M et al.(2008). Phosphorylation and compactness of neurofilaments in multiple sclerosis: indicators of axonal pathology. Exp Neurol vol. 213, (2) 326-335.
10.1016/j.expneurol.2008.06.008
Parkes H, Shorter S, So PW et al. (2008). High resolution 1H nuclear magnetic resonance spectroscopic-based metabolomic urine analysis of experimental autoimmune encephalitis, a model disease of multiple sclerosis. MULTIPLE SCLEROSIS. vol. 14, S86-S87.
Schmierer K, Parkes H, So PW et al. (2008). Magnetization transfer ratio: a predictor of neuronal loss in multiple sclerosis cortical gray matter?. MULTIPLE SCLEROSIS. vol. 14, S219-S220.
Schmierer K, Thavarajah JR, Parkes H et al. (2008). Multiple sclerosis cortical grey matter changes following fixation detected by multimodal magnetic resonance imaging. MULTIPLE SCLEROSIS. vol. 14, S220-S220.
MacManus DG, Miller D, Kappos L et al. (2008). The effect of BG00012 on conversion of gadolinium-enhancing lesions to T1-hypointense lesions. MULTIPLE SCLEROSIS. vol. 14, S163-S163.
Kappos L, Miller D, MacManus D et al. (2008). The efficacy of BG00012 in patients with relapsing-remitting multiple sclerosis: Subgroup analyses from the phase 2B study. NEUROLOGY. vol. 70, A83-A83.
Schmierer K, Wheeler-Kingshott CAM, Tozer DJ et al.(2008). Quantitative magnetic resonance of postmortem multiple sclerosis brain before and after fixation. Magn Reson Med vol. 59, (2) 268-277.
10.1002/mrm.21487
Tofts PS, Jackson JS, Tozer DJ et al.(2008). Imaging cadavers: cold FLAIR and noninvasive brain thermometry using CSF diffusion. Magn Reson Med vol. 59, (1) 190-195.
10.1002/mrm.21456
Schmierer K, Meara SJP, Miller DH et al. (2007). 3D inversion recovery fast spin echo for lesion detection in post mortem multiple sclerosis brain. MULTIPLE SCLEROSIS. vol. 13, S77-S77.
Parkes HG, So PW, Miller DH et al. (2007). High field (9.4T) magnetic resonance reveals cortical lesions in multiple sclerosis brain. MULTIPLE SCLEROSIS. vol. 13, S72-S73.
Parkes HG, Denham M, Schmierer K (2007). High-resolution 1H NMR spectroscopy of multiple sclerosis brain. MULTIPLE SCLEROSIS. vol. 13, S251-S252.
Schmierer K, Tozer DJ, Scaravilli F et al.(2007). Quantitative magnetization transfer imaging in postmortem multiple sclerosis brain. J Magn Reson Imaging vol. 26, (1) 41-51.
10.1002/jmri.20984
Schmierer K, Wheeler-Kingshott CAM, Boulby PA et al.(2007). Diffusion tensor imaging of post mortem multiple sclerosis brain. Neuroimage vol. 35, (2) 467-477.
10.1016/j.neuroimage.2006.12.010
Kappos L, Gold R, Miller D et al. (2007). Safety and tolerability results of a phase 2b extension study of the novel oral fumarate BG00012 for the treatment of relapsing-remitting multiple sclerosis. NEUROLOGY. vol. 68, A276-A277.
Schmierer K, Miller DH (2006). Making sense of magnetic resonance measures in multiple sclerosis: The post mortem evidence. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 77, 1389-1389.
Kappos L, Miller DH, MacManus DG et al. (2006). BG00012, a novel oral fumarate, is effective in patients with relapsing-remitting multiple sclerosis. MULTIPLE SCLEROSIS. vol. 12, S85-S85.
Schmierer K, Parkes HG, So PW et al. (2006). High field-high yield: detecting multiple sclerosis white matter lesions at 9.4 Tesla. MULTIPLE SCLEROSIS. vol. 12, S45-S45.
Kappos L, Miller DH, MacManus DG et al. (2006). Efficacy of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study. JOURNAL OF NEUROLOGY. vol. 253, 27-27.
Symms M, Jäger HR, Schmierer K et al.(2006). A review of structural magnetic resonance neuroimaging. Neuroscience for Neurologists,
Schmierer K, Tozer DJ, Boulby PA et al. (2005). Changes of quantitative magnetic resonance indices following fixation in post-mortem MS brain. MULTIPLE SCLEROSIS. vol. 11, S141-S141.
Schmierer K, Tozer DJ, Scaravilli F et al. (2005). Short T2 relaxation: a potential marker of myelin in post-mortem multiple sclerosis brain. MULTIPLE SCLEROSIS. vol. 11, S141-S141.
Cercignani M, Symms MR, Schmierer K et al.(2005). Three-dimensional quantitative magnetisation transfer imaging of the human brain. Neuroimage vol. 27, (2) 436-441.
10.1016/j.neuroimage.2005.04.031
Lim ET, Schmierer K, Grant D et al. (2005). A comparison of the immunology and histopathology in post mortem multiple sclerosis brain. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 76, 615-616.
Symms M, Jäger HR, Schmierer K et al.(2004). A review of structural magnetic resonance neuroimaging. J Neurol Neurosurg Psychiatry vol. 75, (9) 1235-1244.
10.1136/jnnp.2003.032714
Schmierer K, Scaravilli E, Tozer DJ et al. (2004). Magnetisation transfer as a tool to monitor multiple sclerosis: postmortem evidence. MULTIPLE SCLEROSIS. vol. 10, S229-S229.
Schmierer K, Scaravilli F, Altmann DR et al.(2004). Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol vol. 56, (3) 407-415.
10.1002/ana.20202
Schmierer K, Scaravilli E, Boulby P et al. (2004). Pathological correlates of diffusion tenser imaging (DTI) in post-mortem MS brain. MULTIPLE SCLEROSIS. vol. 10, S229-S229.
Schmierer K (2004). Pathological substrates of quantitative MRI in post mortem multiple sclerosis brain. MULTIPLE SCLEROSIS. vol. 10, S104-S105.
Goodman A, Bar-Or A, Miller A et al. (2004). GLANCE: A double-blind, randomised, placebo-controlled, parallel-group safety study of natalizumab (Antegren) in combination with glatiramer acetate (Copaxone) in subjects with relapsing-remitting multiple sclerosis. JOURNAL OF NEUROLOGY. vol. 251, 176-177.
Schmierer K, Scaravilli E, Altmann DA et al. (2004). Magnetisation transfer ratio: a robust measure of myelin content in post-mortem multiple sclerosis brain. JOURNAL OF NEUROLOGY. vol. 251, 24-24.
Kuhle J, Hardmeier M, Hooghe MD et al.(2004). 8 year follow-up of the European study of Interferon beta-1b (EUSPMS) in secondary progressive MS. NEUROLOGY vol. 62, (7) A489-A490.
Schmierer K, Altmann DR, Kassim N et al.(2004). Progressive change in primary progressive multiple sclerosis normal-appearing white matter: a serial diffusion magnetic resonance imaging study. Mult Scler vol. 10, (2) 182-187.
10.1191/1352458504ms996oa
Schmierer K, Scaravilli F, Barker GJ et al.(2003). Stereotactic co-registration of magnetic resonance imaging and histopathology in post-mortem multiple sclerosis brain. Neuropathol Appl Neurobiol vol. 29, (6) 596-601.
10.1046/j.1365-2990.2003.0497.x
Mottershead JP, Schmierer K, Clemence M et al.(2003). High field MRI correlates of myelin content and axonal density in multiple sclerosis--a post-mortem study of the spinal cord. J Neurol vol. 250, (11) 1293-1301.
10.1007/s00415-003-0192-3
Grosse P, Schulz J, Schmierer K(2003). Diagnostic pitfalls in eosinophilic cryptococcal meningoencephalitis. Lancet Neurol vol. 2, (8)
10.1016/S1474-4422(03)00488-5
Schreiber SJ, Doepp F, Bender A et al.(2003). Diffuse cerebral angiomatosis. Neurology vol. 60, (7) 1216-1218.
10.1212/01.WNL.0000055923.78277.9C
Dobson-Stone C, Danek A, Rampoldi L et al.(2002). Mutational spectrum of the CHAC gene in patients with chorea-acanthocytosis. EUR J HUM GENET vol. 10, (11) 773-+.
10.1038/sj/ejhg.5200866
Dobson-Stone C, Danek A, Rampoldi L et al.(2002). Mutational spectrum of the CHAC gene in patients with chorea-acanthocytosis. Eur J Hum Genet vol. 10, (11) 773-781.
10.1038/sj.ejhg.5200866
Schmierer K, Irlbacher K, Grosse P et al.(2002). Correlates of disability in multiple sclerosis detected by transcranial magnetic stimulation. Neurology vol. 59, (8) 1218-1224.
10.1212/WNL.59.8.1218
Schmierer K, Grosse P, De Camilli P et al.(2002). Paraneoplastic stiff-person syndrome: no tumor progression over 5 years. Neurology vol. 58, (1)
10.1212/WNL.58.1.148
Schmierer K(2002). [Medical history and politics: careers of Fritz Lejeune during the Weimar Republic and national socialism]. Abh Gesch Med Naturwiss (96) 1-292.
Schmierer K, Niehaus L, Röricht S et al.(2000). Conduction deficits of callosal fibres in early multiple sclerosis. J Neurol Neurosurg Psychiatry vol. 68, (5) 633-638.
10.1136/jnnp.68.5.633
Wendling U, Aktas O, Schmierer K et al.(2000). Partial synergy of bisindolylmaleimide with apoptotic stimulus in antigen-specific T cells--implications for multiple sclerosis. J Neuroimmunol vol. 103, (1) 69-75.
10.1016/S0165-5728(99)00214-3
Meyer BU, Röricht S, Schmierer K et al. (1999). First diagnostic applications of transcallosal inhibition in diseases affecting callosal neurones (multiple sclerosis, hydrocephalus, Huntington's disease). Electroencephalogr Clin Neurophysiol Suppl. vol. 51, 233-242.
Kappos L, Polman C, Pozzilli C et al.(1998). Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. LANCET vol. 352, (9139) 1491-1497.
10.1016/S0140-6736(98)10039-9
Schmierer K, Valdueza JM, Bender A et al.(1998). Atypical stiff-person syndrome with spinal MRI findings, amphiphysin autoantibodies, and immunosuppression. Neurology vol. 51, (1) 250-252.
10.1212/WNL.51.1.250
Schmierer K, Roricht S, Niehaus L et al. (1998). Impaired transcallosal inhibition: an early indicator of central conduction deficits in multiple sclerosis. 9TH EUROPEAN CONGRESS OF CLINICAL NEUROPHYSIOLOGY. Editors: Stalberg, EV, DeWeerd, AW, Zidar, J, 119-123.
Meyer BU, Niehaus L, Petrow E et al. (1998). Inhibitory effects of transcranial magnetic motor cortex stimulation in man. 9TH EUROPEAN CONGRESS OF CLINICAL NEUROPHYSIOLOGY. Editors: Stalberg, EV, DeWeerd, AW, Zidar, J, 83-88.
Valdueza JM, Schmierer K, Mehraein S et al.(1996). Assessment of normal flow velocity in basal cerebral veins. A transcranial doppler ultrasound study. Stroke vol. 27, (7) 1221-1225.
10.1161/01.STR.27.7.1221
Return to top